title: Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks.
authors.forename: Laurence
authors.initials: L
authors.lastname: Bouillet
authors.forename: Isabelle
authors.initials: I
authors.lastname: Boccon-Gibod
authors.forename: Denise
authors.initials: D
authors.lastname: Ponard
authors.forename: Christian
authors.initials: C
authors.lastname: Drouet
authors.forename: Jean Yves
authors.initials: JY
authors.lastname: Cesbron
authors.forename: Chantal
authors.initials: C
authors.lastname: Dumestre-Perard
authors.forename: Nicole
authors.initials: N
authors.lastname: Monnier
authors.forename: Joel
authors.initials: J
authors.lastname: Lunardi
authors.forename: Christian
authors.initials: C
authors.lastname: Massot
authors.forename: Anne
authors.initials: A
authors.lastname: Gompel
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D001920:Bradykinin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D065168:Bradykinin Receptor Antagonists; D050718:Complement C1 Inhibitor Protein / Q000235:genetics; D005260:Female; D017353:Gene Deletion; D056828:Hereditary Angioedema Type III / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D007279:Injections, Subcutaneous; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D065168:Bradykinin Receptor Antagonists; D050718:Complement C1 Inhibitor Protein; C065679:icatibant; D001920:Bradykinin